Want to see YDES full AI Analyst Report?
YD Bio Limited (YDES) AI Stock Analysis
Top Page
YD Bio Limited
(NASDAQ:YDES)
The score is primarily weighed down by weak financial performance—worsening losses, persistent and accelerating cash burn, and negative equity in 2025—indicating elevated funding and stability risk. Technicals are mixed with limited momentum and an oversold signal, offering only modest support. Valuation is constrained by negative earnings (negative P/E) and no dividend yield.
YD Bio Limited (YDES) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $420.74M
- Dividend Yield
- ―
- Average Volume (3M)
- 304.29K
- Price to Earnings (P/E)
- -49.5
- Beta (1Y)
- 0.28
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
YD Bio Limited Business Overview & Revenue Model
Company Description
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Ar...
YD Bio Limited Financial Statement Overview
Summary
Financial statement quality is weak. Profitability deteriorated sharply in 2024–2025 (gross profit turned negative and losses widened), operating and free cash flow are consistently negative with accelerating burn in 2025, and equity flipped to negative in 2025, signaling balance-sheet strain and potential recapitalization/dilution risk despite low reported debt.
Income Statement
18Very NegativeBalance Sheet
34NegativeCash Flow
16Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 596.82K | 510.36K | 350.13K | 0 | 0 |
| Gross Profit | 0 | -42.15K | 155.36K | 153.44K | 0 | 0 |
| EBITDA | -2.99M | -8.10M | -1.28M | 22.25K | 3.79M | 8.70M |
| Net Income | -2.97M | -8.31M | -1.41M | 13.56K | 3.79M | 8.70M |
Balance Sheet | ||||||
| Total Assets | 2.95M | 13.78M | 6.86M | 321.21K | 17.93M | 118.06M |
| Cash, Cash Equivalents and Short-Term Investments | 6,312 | 6.01M | 3.13M | 87.10K | 14.13K | 5,403 |
| Total Debt | 0 | 6,764 | 22.55K | 47.58K | 0 | 0 |
| Total Liabilities | 19.00M | 16.64M | 273.98K | 298.22K | 6.74M | 9.11M |
| Stockholders Equity | -16.05M | -2.86M | 6.59M | 22.99K | 11.20M | 108.96M |
Cash Flow | ||||||
| Free Cash Flow | -1.18M | -8.04M | -4.75M | -55.95K | -3.02M | -688.42K |
| Operating Cash Flow | -1.18M | -6.60M | -1.84M | -55.66K | -3.02M | -688.41K |
| Investing Cash Flow | 7.95M | -1.44M | -2.90M | -290 | 100.38M | -1.15M |
| Financing Cash Flow | -6.81M | 10.87M | 7.73M | 113.89K | -97.34M | 1.15M |
YD Bio Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YDES, the sentiment is Positive. The current price of 5.94 is below the 20-day moving average (MA) of 5.97, above the 50-day MA of 5.12, and above the 200-day MA of 5.52, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 52.33 is Neutral, neither overbought nor oversold. The STOCH value of 72.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for YDES.
YD Bio Limited Risk Analysis
YD Bio Limited disclosed 61 risk factors in its most recent earnings report. YD Bio Limited reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskYD Bio Limited Peers Comparison
Overall Rating
- YDES44Neutral
SCNI37Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| YDES | YD Bio Limited | 5.94 | -5.39 | -47.57% | |
| SCNI | Scinai Immunotherapeutics Ltd. Sponsored Adr | 0.47 | -12.23 | -96.29% | |
| ADTX | Aditxt, Inc. | 0.04 | -1406.12 | -100.00% | |
| SPRC | SciSparc Ltd. | 0.68 | -29.20 | -97.74% | |
| CDT | Cdt Equity Inc. | 0.07 | -15624.93 | -100.00% | |
| VRAX | Virax Biolabs Group Ltd. Class A | 1.21 | -12.34 | -91.07% |
YD Bio Limited Corporate Events
YD Bio Files First-Half 2026 Results, Reports Improved Equity Position
YD Bio Limited has filed its unaudited interim consolidated financial statements for the six months ended June 30, 2026, showing total assets of about $10.1 million and a swing in shareholders’ equity from a deficit of $2.9 million at year-end...
YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem
On August 11, 2026, YD Bio Limited launched two chrono-nutrition nutraceutical products in Taiwan as part of a new physician-partnership initiative with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute. The daytime li...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026